RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Clinical trials for RECURRENT GRADE 3 FOLLICULAR LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT GRADE 3 FOLLICULAR LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT GRADE 3 FOLLICULAR LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells target lymphoma after transplant
Disease control OngoingThis study tests a new treatment for people with high-risk B-cell non-Hodgkin lymphoma that has come back after initial therapy. Participants first receive a stem cell transplant, then get an infusion of their own immune cells that have been genetically modified to recognize and …
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 17, 2026 07:59 UTC
-
New hope for relapsed lymphoma: drug cocktail targets cancer cells
Disease control OngoingThis early-stage trial tests a new drug (PCI-32765) combined with two standard treatments (rituximab and bendamustine) in 48 adults with relapsed non-Hodgkin lymphoma. The goal is to find the safest dose and see how well the combination works. Participants have specific types of …
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: Kami Maddocks, MD • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Engineered T-Cells show promise in lymphoma fight
Disease control OngoingThis early-phase study tests a new immune therapy for people with high-risk or returning non-Hodgkin lymphoma. After a stem cell transplant, patients receive specially modified T-cells designed to find and attack cancer cells. The main goal is to check safety and find the best do…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New CMV strategy aims to protect stem cell transplant patients from dangerous infection
Disease control OngoingThis study looks at a modified approach to prevent and treat cytomegalovirus (CMV) infection in people who have had a donor stem cell transplant for blood cancers or disorders. About 153 participants are involved, and the goal is to see if changing when and how anti-CMV drugs are…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
New hope for Tough-to-Treat lymphoma: targeted drug shows promise
Disease control OngoingThis study tests a drug called ibrutinib in 41 adults with follicular lymphoma that has come back or no longer responds to standard treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The main goal is to see how many patients have their tumors shr…
Matched conditions: RECURRENT GRADE 3 FOLLICULAR LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:53 UTC